Kelun Pharmaceutical projects 2026 related-party transactions with Sino Biopharmaceutical

Sichuan Kelun Pharmaceutical anticipates ordinary related-party transactions with Sino Biopharmaceutical Limited totaling no more than RMB 257.73m for 2026. This includes projected purchases of materials and acceptance of services amounting to RMB 72.71m, and sales of goods and provision of services reaching RMB 185.02m. These transactions are priced at market rates and align with the company's normal production and operation.

The company also disclosed its remuneration management system for directors and senior management, emphasizing compensation linked to company scale, operating targets, and performance. For non-independent directors concurrently holding senior management positions, their remuneration will follow the senior management compensation guidelines.

For the first eleven months of 2025, actual related-party transactions with Sino Biopharmaceutical Limited amounted to RMB 18,259.85m, showing a significant variance from the previously estimated RMB 36,939.00m. This discrepancy is attributed to the inherent uncertainties in forecasting. Sino Biopharmaceutical Limited reported total assets of HK$1,279,224.70m and a net profit of HK$29,019.70m for the first half of 2025.